Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
Stock Information for Anebulo Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.